SCHEMBL290459

SCHEMBL290459

N=C(CCC(=O)OC(=O)CCCCC(=O)O)OC(=O)CCCCC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
TSHR P16473 5/20 0.44
NFKB1 P19838 2/20 0.44
PMP22 Q01453 1/20 0.44
SLC22A6 Q4U2R8 2/20 0.40
GPR84 Q9NQS5 4/20 0.38
FFAR1 O14842 2/20 0.38
FFAR4 Q5NUL3 2/20 0.38
AKR1B1 P15121 1/20 0.38
CYP2D6 P10635 1/20 0.38
FOLH1 Q04609 1/20 0.38
ALDH1A1 P00352 3/20 0.38
PPARG P37231 5/20 0.37
PPARD Q03181 5/20 0.37
PPARA Q07869 5/20 0.37
HDAC11 Q96DB2 4/20 0.37
TLR2 O60603 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
FABP4 P15090 2/20 0.37
PTPN1 P18031 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1230057 0.98 TSHR (0.48) LMNATSHRNFKB1PMP22SLC22A6
SCHEMBL1870547 0.98 TSHR (0.48) LMNATSHRNFKB1PMP22SLC22A6
SCHEMBL905402 0.98 TSHR (0.48) LMNATSHRNFKB1PMP22SLC22A6
SCHEMBL379359 0.98 TSHR (0.48) LMNATSHRNFKB1PMP22SLC22A6
SCHEMBL905699 0.98 TSHR (0.48) LMNATSHRNFKB1PMP22SLC22A6
SCHEMBL905720 0.98 TSHR (0.48) LMNATSHRNFKB1PMP22SLC22A6
SCHEMBL34381 0.96 TSHR (0.48) LMNATSHRNFKB1PMP22SLC22A6
Ethylene Glycol SCHEMBL6523934 0.90 TSHR (0.44) LMNATSHRNFKB1PMP22SLC22A6
SCHEMBL43574 0.89 EGLN1 (0.43) LMNATSHRNFKB1PMP22SLC22A6
SCHEMBL2593466 0.87 TSHR (0.41) LMNATSHRNFKB1PMP22SLC22A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4683964-A2 POLY(ETHYLENE GLYCOL) BASED DENDRIMER-LIKE HYPERBRANCHED MACROMOLECULES, METHODS OF PREPARATION AND USE THEREOF Ocular Therapeutix, Inc. (US) 2026-01-28 EP claimed
EP-4665307-A1 BIODEGRADABLE MICROPARTICLES FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF Ocular Therapeutix, Inc. (US) 2025-12-24 EP claimed
EP-4630058-A2 CHEMICAL TISSUE ABLATION WITH HYDROGEL MATRIX AND CORRESPONDING MEDICAL APPLICATIONS Pramand LLC (US) 2025-10-15 EP claimed
EP-4568658-A1 ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF Ocular Therapeutix, Inc. (US) 2025-06-18 EP claimed
US-20250144012-A1 INTRACAMERAL DRUG DELIVERY DEPOTS INCEPT, LLC 2025-05-08 US claimed
CN-119947711-A Organogels for sustained drug delivery, methods of preparation and uses thereof 视尔普斯眼科公司 2025-05-06 CN claimed
US-12251466-B2 Single solution hydrogels with covalent bonding formed in situ, composition design and medical procedures using the hydrogels Pramand LLC (US) 2025-03-18 US claimed
EP-4518920-A1 WATER ACTIVATED HYDROGEL-BASED MEDICAL PATCHES, FLEXIBLE SUBSTRATES AND METHODS OF MAKING AND USING SUCH PATCHES Pramand LLC (US) 2025-03-12 EP claimed
EP-4511074-A1 SINGLE SOLUTION HYDROGELS WITH COVALENT BONDING FORMED IN SITU, COMPOSITION DESIGN AND MEDICAL PROCEDURES USING THE HYDROGELS Pramand LLC (US) 2025-02-26 EP claimed
WO-2023205051-A9 SINGLE SOLUTION HYDROGELS WITH COVALENT BONDING FORMED IN SITU, COMPOSITION DESIGN AND MEDICAL PROCEDURES USING THE HYDROGELS Pramand LLC (US) 2024-11-14 WO claimed
EP-4197527-A1 INTRACAMERAL DRUG DELIVERY DEPOTS Incept, LLC (US) 2023-06-21 EP claimed
US-20230183475-A1 GELLING SOLUTIONS FOR ADMINISTRATION OF COMPOUNDS TO THE INNER EAR SPIRAL THERAPEUTICS INC. 2023-06-15 US claimed
WO-2021231563-A9 GELLING SOLUTIONS FOR ADMINISTRATION OF COMPOUNDS TO THE INNER EAR SPIRAL THERAPEUTICS INC. (US) 2023-05-11 WO claimed
EP-4149431-A1 GELLING SOLUTIONS FOR ADMINISTRATION OF COMPOUNDS TO THE INNER EAR Spiral Therapeutics Inc. (US) 2023-03-22 EP claimed
CN-115666511-A Gelling solution for applying compounds to the inner ear 斯皮拉尔诊疗有限公司 2023-01-31 CN claimed
US-20220401356-A1 INTRACAMERAL DRUG DELIVERY DEPOTS INCEPT, LLC 2022-12-22 US claimed
EP-4090261-A1 METHODS AND DEVICES FOR IN SITU FORMED NERVE CAP WITH RAPID RELEASE Tulavi Therapeutics, Inc. (US) 2022-11-23 EP claimed
CN-113827766-B Drug-loaded surgical sealant and preparation method and application thereof 赛克赛斯生物科技股份有限公司 2022-05-24 CN claimed
WO-2021231563-A1 GELLING SOLUTIONS FOR ADMINISTRATION OF COMPOUNDS TO THE INNER EAR SPIRAL THERAPEUTICS INC. (US) 2021-11-18 WO claimed
US-10272164-B2 Implants and biodegradable tissue markers INCEPT, LLC (US) 2019-04-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250144012-A1 INTRACAMERAL DRUG DELIVERY DEPOTS MMP1, UACA, IDE LMNA 2426/4885TSHR 994/4885NFKB1 816/4885
US-20220401356-A1 INTRACAMERAL DRUG DELIVERY DEPOTS MMP1, UACA, IDE LMNA 2426/4885TSHR 994/4885NFKB1 816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.